Screener
Immunome IMNM Payments to Acquire in Process Research and Development
Payments to Acquire in Process Research and Development at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (161) | (62) |
| Net cash used in operating activities | (58,638) | (53,055) |
| Cash flows from investing activities: | ||
| Purchases of in-process research and development assets | (9,014) | (6,246) |
| Purchases of property and equipment | (3,002) | (3,665) |
| Maturities of marketable securities | — | 15,000 |
| Net cash (used in) provided by investing activities | (12,016) | 5,089 |
| Cash flows from financing activities: |
Item 1. Financial Statements.
FAQ
- What is Immunome's payments to acquire in process research and development?
- Immunome (IMNM) reported payments to acquire in process research and development of $9.01M in Q1 2026.
- How has Immunome's payments to acquire in process research and development changed year-over-year?
- Immunome's payments to acquire in process research and development increased by 44.3% year-over-year, from $6.25M to $9.01M.
- What does payments to acquire in process research and development mean?
- Payments to Acquire in Process Research and Development
Ask your AI about Immunome's payments to acquire in process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude